Drugs / Filibuvir
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01210404 | Feb → May 2011 | chronic hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00918476 | Jun 2010 → Feb 2011 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00875628 | Apr 2009 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00861458 | Apr → Jun 2009 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00823745 | Jan → Feb 2009 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00671671 | Apr → Dec 2008 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00651027 | Feb → Sep 2008 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00445315 | Jan 2007 → Jun 2008 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT00987337 | Nov 2009 → Jan 2012 | hepatitis C virus infection | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00720434 | Aug 2008 → Mar 2010 | chronic hepatitis C virus infection | Pfizer | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01051232 Comparator | Feb → Apr 2010 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Filibuvir | “PF-00868554 (Filibuvir) following single oral administrations of PF-00868554 (Filibuvir) under fasting conditions in Japanese healthy adult volunteers” NCT01051232 ↗4“Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.” PMID 21488067 ↗ Jul 2011 |
| Known as | PF-00868554 | “PF-00868554 (Filibuvir) following single oral administrations of PF-00868554 (Filibuvir) under fasting conditions in Japanese healthy adult volunteers” NCT01051232 ↗5“Single dose of 750 mg PF-00868554 as a solution and tablets.” NCT00861458 ↗ |
| Known as | PF-868554 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00651027 ↗ |
| Action | Inhibit | “non-nucleoside inhibitor filibuvir” PMID 21488067 ↗ Jul 2011 |
| Modality | Small molecule | “non-nucleoside inhibitor filibuvir” PMID 21488067 ↗ Jul 2011 |
| Route | Oral | “multiple oral doses of PF-00868554” NCT00445315 ↗ |
| Target | CYP3A4 | “Filibuvir, a CYP3A4 inhibitor” NCT01210404 ↗ |